Instead, engineered T cells + CD40 agonist, which we previously showed to promote the persistence of engineered T cells in autochthonous PDA [36], promoted tumor cytoplasmic Cxcl9/Cxcl10 (Fig. 6C-D, Supplementary Fig. 5A), indicating that immunotherapy alters the subcellular localization of Cxcr3 ligands in tumor cells. This evidence concerns the gene CXCL9 and Patent ductus arteriosus.